|
1
|
Bikle DD, Feingold KR, Anawalt B, Boyce A,
Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM,
Hofland J, et al: Vitamin D: production, metabolism and mechanisms
of action. 2021, Wilson DP: South Dartmouth (MA): MDText.com;
|
|
2
|
Bikle DD: Vitamin D metabolism, mechanism
of action, and clinical applications. Chem Biol. 21:319–329. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Christakos S, Dhawan P, Verstuyf A,
Verlinden L and Carmeliet G: Vitamin D: Metabolism, molecular
mechanism of action, and pleiotropic effects. Physiol Rev.
96:365–408. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alshahrani F and Aljohani N: Vitamin D:
Deficiency, sufficiency and toxicity. Nutrients. 5:3605–3616. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Saponaro F, Saba A and Zucchi R: An update
on vitamin D metabolism. Int J Mol Sci. 21:65732020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
DeLuca HF: Vitamin D: Historical overview.
Vitam Horm. 100:1–20. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Trump DL and Aragon-Ching JB: Vitamin D in
prostate cancer. Asian J Androl. 20:244–252. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carlberg C and Muñoz A: An update on
vitamin D signaling and cancer. Semin Cancer Biol. 79:217–230.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Song ZY, Yao Q, Zhuo Z, Ma Z and Chen G:
Circulating vitamin D level and mortality in prostate cancer
patients: A dose-response meta-analysis. Endocr Connect.
7:R294–R303. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dou R, Ng K, Giovannucci EL, Manson JE,
Qian ZR and Ogino S: Vitamin D and colorectal cancer: Molecular,
epidemiological and clinical evidence. Br J Nutr. 115:1643–1660.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou J, Ge X, Fan X, Wang J, Miao L and
Hang D: Associations of vitamin D status with colorectal cancer
risk and survival. Int J Cancer. 149:606–614. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Negri M, Gentile A, de Angelis C, Montò T,
Patalano R, Colao A, Pivonello R and Pivonello C: Vitamin D-induced
molecular mechanisms to potentiate cancer therapy and to reverse
drug-resistance in cancer cells. Nutrients. 12:17982020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mimori K, Tanaka Y, Yoshinaga K, Masuda T,
Yamashita K, Okamoto M, Inoue H and Mori M: Clinical significance
of the overexpression of the candidate oncogene CYP24 in esophageal
cancer. Ann Oncol. 15:236–241. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shiratsuchi H, Wang Z, Chen G, Ray P, Lin
J, Zhang Z, Zhao L, Beer D, Ray D and Ramnath N: Oncogenic
potential of CYP24A1 in lung adenocarcinoma. J Thorac Oncol.
12:269–280. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Osanai M and Lee GH: CYP24A1-induced
vitamin D insufficiency promotes breast cancer growth. Oncol Rep.
36:2755–2762. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
WHO Classification of Tumours Editorial
Board (ed), . Breast tumours. Lyon (France): International Agency
for Research on Cancer; 2019, (WHO classification of tumours
series, 5th edition, volume 2).
|
|
17
|
Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J
and Shi B: Breast cancer intrinsic subtype classification, clinical
use and future trends. Am J Cancer Res. 5:2929–2943.
2015.PubMed/NCBI
|
|
18
|
Ades F, Zardavas D, Bozovic-Spasojevic I,
Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C and
Piccart M: Luminal B breast cancer: Molecular characterization,
clinical management, and future perspectives. J Clin Oncol.
32:2794–2803. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yin L, Duan JJ, Bian XW and Yu SC:
Triple-negative breast cancer molecular subtyping and treatment
progress. Breast Cancer Res. 22:612020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang X, Harbeck N, Jeschke U and
Doisneau-Sixou S: Influence of vitamin D signaling on hormone
receptor status and HER2 expression in breast cancer. J Cancer Res
Clin Oncol. 143:1107–1122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Estébanez N, Gómez-Acebo I, Palazuelos C,
Llorca J and Dierssen-Sotos T: Vitamin D exposure and risk of
breast cancer: A meta-analysis. Sci Rep. 8:90392018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hossain S, Beydoun MA, Beydoun HA, Chen X,
Zonderman AB and Wood RJ: Vitamin D and breast cancer: A systematic
review and meta-analysis of observational studies. Clin Nutr ESPEN.
30:170–184. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Voutsadakis IA: Vitamin D receptor (VDR)
and metabolizing enzymes CYP27B1 and CYP24A1 in breast cancer. Mol
Biol Rep. 47:9821–9830. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Manson JE, Cook NR, Lee IM, Christen W,
Bassuk SS, Mora S, Gibson H, Gordon D, Copeland T, D'Agostino D, et
al: Vitamin D supplements and prevention of cancer and
cardiovascular disease. N Engl J Med. 380:33–44. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Park JW, Kim KA and Park JY: Effects of
ketoconazole, a CYP4F2 inhibitor, and CYP4F2*3 genetic polymorphism
on pharmacokinetics of vitamin K1. J Clin Pharmacol. 59:1453–1461.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Czyrski A, Resztak M, Świderski P, Brylak
J and Główka FK: The overview on the pharmacokinetic and
pharmacodynamic interactions of triazoles. Pharmaceutics.
13:19612021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Segovia-Mendoza M, González-González ME,
Barrera D, Díaz L and García-Becerra R: Efficacy and mechanism of
action of the tyrosine kinase inhibitors gefitinib, lapatinib and
neratinib in the treatment of HER2-positive breast cancer:
Preclinical and clinical evidence. Am J Cancer Res. 5:2531–2561.
2015.PubMed/NCBI
|
|
29
|
Kim HJ, Lee YM, Ko BS, Lee JW, Yu JH, Son
BH, Gong JY, Kim SB and Ahn SY: Vitamin D deficiency is correlated
with poor outcomes in patients with luminal-type breast cancer. Ann
Surg Oncol. 18:1830–1836. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Blackmore KM, Lesosky M, Barnett H, Raboud
JM, Vieth R and Knight JA: Vitamin D from dietary intake and
sunlight exposure and the risk of hormone-receptor-defined breast
cancer. Am J Epidemiol. 168:915–924. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
McCullough ML, Rodriguez C, Diver WR,
Feigelson HS, Stevens VL, Thun MJ and Calle EE: Dairy, calcium, and
vitamin D intake and postmenopausal breast cancer risk in the
cancer prevention study II nutrition cohort. Cancer Epidemiol
Biomark Prev. 14:2898–2904. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kawase T, Matsuo K, Suzuki T, Hirose K,
Hosono S, Watanabe M, Inagaki M, Iwata H, Tanaka H and Tajima K:
Association between vitamin D and calcium intake and breast cancer
risk according to menopausal status and receptor status in Japan.
Cancer Sci. 101:1234–1240. 2010. View Article : Google Scholar : PubMed/NCBI
|
